Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most […]
March 24, 2020
Journal of Immunotherapy for Cancer 2020 February [Link] Hotta K, Fujimoto N Abstract Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both […]
March 11, 2020
International Journal of Environmental Research and Public Health 2020 February 10 [Link] Töreyin ZN, Ghosh M, Göksel Ö, Göksel T, Godderis L Abstract Malignant pleural mesothelioma (MPM) is mainly related to previous asbestos exposure. There is still dearth of information on non-invasive biomarkers to detect MPM at early stages. Human studies on exhaled breath biomarkers […]
February 25, 2020
Cancers 2020 February 7 [Link]
February 17, 2020
Biomarker Research 2020 January 8 [Link] Kim MK, Kim HW, Jang M, Oh SS, Yong SJ, Jeong Y, Jung SH, Choi JW Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural and outer layer of tissues surrounding the lungs. MPM is primarily caused by occupational exposure to […]
January 21, 2020
Lung Cancer 2019 November 18 [Link] Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B Abstract OBJECTIVES: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with dismal prognosis but variable course of disease. To support diagnosis and to risk stratify patients, more reliable biomarkers are warranted. Emerging evidence underlines a […]
December 10, 2019
Clinical Lung Cancer 2019 October 25 [Link] Paajanen J, Ilonen I, Lauri H, Järvinen T, Sutinen E, Ollila H, Rouvinen E, Lemström K, Räsänen J, Ritvos O, Koli K, Myllärniemi M Abstract BACKGROUND: Previous preclinical studies have shown that activin A is overexpressed in malignant pleural mesothelioma (MPM), associates with cancer cachexia, and is observed […]
November 28, 2019
Cytopathology 2019 November 12 [Link] LThakfi W, Gazzo S, Blanchet M, Isaac S, Piaton E, Villeneuve L, Glehen O, Gilly FN, Brevet M Abstract OBJECTIVE: Diffuse malignant peritoneal mesothelioma (DMPM), represents 30% of all malignant mesothelioma, and is characterized by a difficult diagnosis and different presentations. Immunohistochemistry has improved the diagnostic sensitivity and specificity in […]
November 21, 2019
Frontiers in Cell and Developmental Biology 2019 October 1 [Link] Johnson TG, Schelch K, Mehta S, Burgess A, Reid G Abstract Lung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates of all cancer types, primarily due to a lack of effective treatment options for most patients. Targeted therapies have […]
October 31, 2019
Biotechnic & Histochemistry 2019 October 1 [Link] Kocaman N, Artaş G Abstract Malignant mesothelioma (MM) is a rare tumor of serous surfaces that has a poor prognosis. Cancer is a multistage process by which cells undergo metabolic and behavioral changes that cause excessive and untimely proliferation. Asprosin (ASP) and meteorin-like (METRNL) are two peptides associated […]
October 15, 2019